Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
News May 06, 2014

Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.
RELATED ARTICLES
Gene Therapy Could End Transfusions for Blood Disorder Patients
NewsBeta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.
READ MOREHow City Life Has Changed the Bumblebee Genome
NewsLife in the city is a double-edged sword for bumblebees. Subtle differences in their genome show how these important insects have adapted to the food-rich but fragmented city habitat.
READ MOREHow Do Plants Avoid UV Damage?
NewsPublic health warnings against too much exposure to UV are based on sound advice: UV rays can damage DNA and cause cancers and other diseases. Plants, however, cannot avoid UV. A new study now shows how plants' DNA repair system helps combat constant UV exposure.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018
Login
You must be logged in to post a comment.